Status:
COMPLETED
The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma
Lead Sponsor:
Centre National de Greffe de Moelle Osseuse
Conditions:
Multiple Myeloma
Eligibility:
All Genders
Up to 61 years
Phase:
PHASE3
Brief Summary
Autologous peripheral blood stem cell (PBSC) transplantation is now considered standard therapy in patients (\< 65 ans) with multiple myeloma. The Intergroupe Francophone du Myelome conducted a random...
Eligibility Criteria
Inclusion
- patients less than 61 years of age
- Durie Salmon stage II or III
- written and informed consent
Exclusion
- Prior treatment for myeloma
- ECOG performance score of 4
- Positive HIV test
- Chronic respiratory disease (DLco \< 60%)
- Systolic ejection fraction \< 50%
- Pregnant or nursing women
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
202 Patients enrolled
Trial Details
Trial ID
NCT00207805
Start Date
May 1 2003
Last Update
January 27 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre National de Greffe de Moelle Osseuse
Tunis, Tunisia, 1006